Practice Test Geeks(AAC) Alzheimer's Association Certification Practice Test
← All AAC Flashcard Decks

Research & Clinical Trials Awareness Flashcards

7 cards from real AAC practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Research & Clinical Trials Awareness flashcards as text

  1. What is the primary purpose of a placebo-controlled clinical trial in Alzheimer's research?

    Answer: To compare outcomes between those receiving the treatment and those receiving an inactive substance

    A placebo-controlled trial compares the experimental treatment against an inactive substance to isolate the drug's true effect.

  2. Which biomarker is most commonly measured in cerebrospinal fluid (CSF) as evidence of Alzheimer's pathology in research studies?

    Answer: Amyloid-beta and tau proteins

    CSF levels of amyloid-beta 42 and tau (both total and phosphorylated) are the gold-standard biomarkers for Alzheimer's pathology.

  3. What does 'informed consent' require before enrolling a person with Alzheimer's in a clinical trial?

    Answer: Confirmation that the participant or legally authorized representative fully understands risks, benefits, and alternatives

    Informed consent requires that the participant or their legally authorized representative understand and voluntarily agree to all aspects of the study.

  4. What is the significance of the Alzheimer's Association's TrialMatch program?

    Answer: It connects patients, caregivers, and healthy volunteers with relevant clinical trials

    TrialMatch is a free service that matches individuals with Alzheimer's or those at risk to appropriate clinical trials based on their profile.

  5. In Alzheimer's drug trials, what does the term 'cognitive endpoint' refer to?

    Answer: A measurable outcome related to thinking, memory, or daily function used to assess treatment effect

    Cognitive endpoints are standardized scores measuring memory, language, or daily functioning used to determine whether a treatment works.

  6. Why is recruitment of diverse populations especially important in Alzheimer's clinical trials?

    Answer: Because Alzheimer's risk, prevalence, and treatment response may differ across racial and ethnic groups

    Including diverse populations ensures that trial results are generalizable and captures potential differences in disease risk, progression, and drug response.

  7. What is a 'longitudinal study' in the context of Alzheimer's research?

    Answer: A study that follows the same participants over an extended period to track changes over time

    Longitudinal studies track the same individuals repeatedly over months or years to observe how cognitive decline or biomarkers change over time.